|
|
Women's Health: Worldwide Prescription Drug Markets, 4th Edition |
|
|
|
Women’s health encompasses all different areas of medicine and it would be a monumental task to address all of the areas that affect women. This report will concentrate on disorders that affect the female reproductive system and other disorders where there is at least a 70% preponderance of women affected by the disorder. The worldwide prescription drug market for women’s health consists of total manufacturers’ revenues from the following product categories:
- Autoimmune diseases
- Cancer
- Gynecological and Sexually Transmitted Diseases
- Hormones
- Osteoporosis
- Urinary Disorders
Women's Health: Worldwide Prescription Drug Markets, represents the fourth time that Kalorama Information has tackled the women's health pharmaceutical market. Revenues from these segments are not reported in total, as certain segments affect both men and women. The analysis and market data in this report estimate revenues associated with therapeutics for women only. Segmentation within each category is by major drug type and by geographic region (U.S., Europe, Japan, ROW). All market data pertain to the U.S. market at the manufacturers’ level. Data are expressed in current U.S. dollars. The base year for data was 2007. forecast data are provided for each of the years 2008 through 2012. Historical, base year, and forecast data are provided for each market segment. Market shares are provided for each market segment for the 2007 base year.
In addition to market data, the report contains extensive product pipeline information, competitor profiles, and discussions of the major industry issues and trends shaping the market.
The information and analysis presented in this report are based on an extensive survey of senior management in the prescription women’s health drug industry. Background information was obtained from a comprehensive search of published literature and reports obtained from various government, business, medical trade, and international journals. Key information from published literature was used to conduct interviews with over 40 industry executives and product managers to validate and obtain expert opinion on current and future trends in the women’s health industry. Interviews were also used to confirm and/or adjust market size and market share estimates, as well as in formulating market projections.
All market data pertains to the U.S. market at the manufacturers’ level. Data are expressed in current U.S. dollars. The base year for data was 2008. Historical data are provided for each of the years 2006 and 2007, and forecast data are provided for each of the years 2009 through 2014. Historical, base year, and forecast data are provided for each market segment. Market shares are provided for each market segment for the 2008 base year |
|
|
|
Table of Contents : |
CHAPTER ONE:EXECUTIVE SUMMARY
- Scope and Methodology
- Size and Growth of the Market
- Total Market Size and Forecast
- Market Outlook
CHAPTER TWO: INTRODUCTION AND OVERVIEW
- History of Women’s Health
- Female Reproductive System
- Hormone Regulation
- Market Trends
- Women’s Health Initiative
- Women’s Health Office Act of 2007
- Perimenopausal Use of Contraceptives
- Insurance Coverage for Contraceptives
- Oral Contraceptives in Japan
- Ovarian Cancer Test
- Estrogen Labeling
- Osteoporosis Drug Opportunities in Asia
- Women’s Healthcare Access
- Demographics
CHAPTER THREE: AUTOIMMUNE DISEASES
- Overview
- Prevalence
- Chronic Fatigue Syndrome
- Treatment
- Fibromyalgia
- Treatment
- Rheumatoid Arthritis
- Treatment
- Scleroderma
- Treatment
- Sjogren’s Syndrome
- Treatment
- Systemic Lupus Erythematosus
- Treatment
- Market Size and Growth
- Geographical Market Analysis
- Research and Development
- Ampligen
- Actemra
- Apilimod
- Arcoxia
- Cimza
- Denosumab
- INCBO18424
- Interleukin (IL-1)
- LymphoStat-B
- Milnacipran
- Prestara
- Riquent
- Veldona
- Competitive Market
CHAPTER FOUR: CANCER
- Overview
- Incidence and Mortality
- Breast Cancer
- Overview
- Treatment
- Cervical Cancer
- Overview
- Treatment
- Endometrial Cancer
- Overview
- Treatment
- Ovarian Cance
- Overview
- Treatment
- Vaginal Cancer
- Overview
- Treatment
- Market Size and Growth
- Geographical Market Analysis
- Research and Development
- Advexin
- Alvespimycin
- Arzoxifene
- Avastin
- Axtinib
- Cervarix
- Herceptin
- Karenitecin
- Pazopanib
- Pertuzumab
- Tykerb
- Yondeli
- Competitive Market
CHAPTER FIVE: GYNECOLOGICAL INFECTIONS AND SEXUALLY TRANSMITTED DISEASES
- Overview
- Incidence and Prevalence
- AIDS
- Overview
- Treatment
- Agenerase
- Aptivus
- Combivir
- Crixivan
- Entriva
- Fortovase
- Fuzeon
- Hivid
- Intelence
- Invirase
- Isentress
- Kaletra
- Kivexa
- Lexiva
- Prezista
- Rescriptor
- Reyataz
- Selzentry
- Sustiva
- Trizivir
- Truvada
- Viracept
- Viramune
- Bacterial Vaginosis
- Overview
- Treatment
- Cervical Dysplasia
- Overview
- Treatment
- Chlamydia
- Overview
- Treatment
- Condyloma Acuminata
- Overview
- Treatment
- Aldara
- Alferon N Injection
- Condylox
- Gardasil
- Genital Herpes
- Overview
- Treatment
- Zovirax
- Gonorrhea
- Overview
- Treatment
- Hepatitis
- Overview
- Treatment
- Baraclude
- Pelvic Inflammatory Disease
- Overview
- Treatment
- Syphilis
- Overview
- Treatment
- Toxic Shock Syndrome
- Overview
- Treatment
- Yeast Infections
- Overview
- Treatment
- Market Size and Growth
- Geographical Market Analysis
- Research and Development
- Ampligen
- Bevirimat
- Boceprevir
- Clevudine
- Elvitegravir
- GS 9137
- Hepaconda
- IC41
- IDX899
- Loctero
- R7128
- RDEA806
- SPO1A
- Telaprevir
- TMC278
- Vicriviroc
- VRX496
- Competitive Market
CHAPTER SIX: HORMONE-RELATED DISORDERS
- Overview
- Statistics
- Contraception
- Overview
- Treatment
- Oral Contraceptives
- Depo-Provera
- Birth Control Patch
- Vaginal Ring
- Emergency Contraception and Early Option
- Implant
- IUD
- Endometriosis
- Overview
- Treatment
- Fibroids
- Overview
- Treatment
- Infertility
- Overview
- Treatment
- Menopause
- Overview
- Treatment
- Menstrual Disorders
- Amenorrhea
- Treatment
- Dysmenorrhea
- Treatment
- Sexual Dysfunction
- Overview
- Treatment
- Market Size and Growth
- Geographical Market Analysis
- Research and Development
- Alista
- LibiGel
- NOMAC/E2
- Ophena
- Org 36286
- Competitive Market
CHAPTER SEVEN: OSTEOPOROSIS
- Overview
- Prevalence
- Prevention
- Treatment
- Market Size and Growth
- Geographical Market Analysis
- Research and Development
- Arzoxifene
- Denosumab
- Fablyn
- MK-0822 (Odanacatib)
- Preos
- SUN E3001
- Viviant
- Competitive Market
CHAPTER EIGHT: URINARY BLADDER DISORDERS
- Overview
- Incidence and Prevalence
- Cystitis
- Overview
- Treatment
- Incontinence
- Overview
- Treatment
- Overactive Bladder
- Treatment
- Alternative Treatments
- Interstitial Cystitis
- Overview
- Treatment
- Market Size and Growth
- Geographical Market Analysis
- Research and Development
- Oxybutynin Gel
- Anturol
- PSD503
- Competitive Market
CHAPTER NINE: WORLD MARKET SUMMARY
- Overview
- Total Market Size and Forecast
- Market Analysis
CHAPTER TEN:CORPORATE PROFILES AND ANALYSIS
APPENDIX: COMPANY DIRECTORY: MAJOR SUPPLIERS
TABLE OF EXHIBITS
CHAPTER ONE: EXECUTIVE SUMMARY
- Table 1-1: The World Market Women’s Disorders 2006-2013
- Figure 1-1: The World Market Women’s Disorders 2006-2013
CHAPTER TWO: INTRODUCTION AND OVERVIEW
- Table 2-1: World Life Expectancy at Birth in Selected Countries by Sex, 2007
- Figure 2-1: Female Advantage in Life Expectancy at Birth in Selected Countries, 2007 (Difference, in Years, between Females and Males)
- Table 2-2: World Population Growth, by Total World Population and Selected Country or Regions and Selected Characteristics
- Figure 2-2: World Population Growth by Sex 2000, 2005, 2010, 2020, 2025 (in millions)
- Figure 2-3: United States Population Growth by Sex 2000, 2005, 2010, 2020, 2025 (in millions)
- Figure 2-4: Five Major European Countries* Population Growth by Sex 2000, 2005, 2010, 2020, 2025 (in millions)
- Figure 2-5: Japan Population Growth by Sex 2000, 2005, 2010, 2020, 2025 (in millions)
- Table 2-3: World Female Population Growth by Selected Country or Regions and Selected Age Group
- Figure 2-6: World Female Population Growth by Selected Age Group 2000, 2005, 2010, 2020, 2025 (in millions)
- Figure 2-7: United States Female Population Growth by Selected Age Group 2000, 2005, 2010, 2020, 2025 (in millions)
- Figure 2-8: Five Major European Countries* Female Population Growth by Selected Age Group 2000, 2005, 2010, 2020, 2025 (in millions)
- Figure 2-9: Japan Female Population Growth by Selected Age Group 2000, 2005, 2010, 2020, 2025 (in millions)
CHAPTER THREE: AUTOIMMUNE DISEASES
- Table 3-1: Estimated Female Prevalence of Autoimmune Diseases by Type and Geographical Distribution, Estimated 2008
- Table 3-2: The World Market for Autoimmune Disease Drugs for Women 2006-2013
- Figure 3-1: The World Market for Autoimmune Disease Drugs for Women 2006-2013
- Table 3-3: The World Market for Autoimmune Disease Drugs for Women by Disease Type 2006-2013
- Figure 3-4: The World Market for Autoimmune Disease Drugs for
- Table 3-4 Women, Revenues by Disease Type 2006-2013
- Figure 3-3: The World Market for Autoimmune Disease Drugs for
- Figure 3-4: The World Market for Autoimmune Disease Drugs for Women, Market Share by Disease Type 2013
- Table 3-8: The World Market for Autoimmune Disease Drugs for
- Women Market Analysis by Region/Country, 200
|
|
|
|
Published By : Kalorama Information |
|
|
Category
Related Report:
Automotive,
Automobile,
Aerospace & Aviation,
Banking,
Consumer Goods,
Construction,
Chemicals,
Defense,
Diabetes,
Disease,
Drinks,
Energy,
Electronics,
Financial
,
Food & Drinks,
Glass,
Healthcare,
Insurance,
Information technology,
Investment,
Industrial Gases,
Industry Profile,
Medical,
Media,
Marketing,
Miscellaneous,
Metals & Mining,
Nuclear Energy,
Oil & Gas,
Power,
Real Estate,
Software,
Solar,
Transportation
|
|
|
|
